Recent announcements:
Proximagen and Altacor sign agreement for 5HT2c.
Proximagen signs strategic partnership agreement with Lundbeck.
Proximagen update by Edison Investment Research.
Proximagen acquires two CNS drug development programmes from GlaxoSmithKline.
Proximagen hosts European Investor Seminar in London
Upsher-Smith Laboratories Inc increases its stake in Proximagen
Proximagen enters into agreement with Ligand Pharmaceuticals Inc.
Proximagen announces sale of sabcomeline
NIH funds Phase II clinical trial on naluzotan
Proximagen sublicenses rights to tonabersat
Proximagen announces positive efficacy results in NIH epilepsy studies
Links to more press related content: